AADVL18P1 – An Open-Label Feasibility Study to Assess the Safety and Pharmacokinetics of Enasidenib in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia R/R-AML with an Isocitrate Dehydrogenase-2 IDH2 Mutation”,


Total Award Amount

  • 20150.00
  • Direct Costs

  • 15500.00
  • Sponsor Award Id

  • Contributor

  • Aman Wadhwa   Investigator  
  • Ana Xavier   Investigator  
  • Julie Wolfson-Stockman M.D.   Investigator  
  • Matthew Kutny M.D.   Principal Investigator